Twist Bioscience Corp [TWST] stock is trading at $40.22, up 5.73%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TWST shares have gain 9.09% over the last week, with a monthly amount glided 25.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Twist Bioscience Corp [NASDAQ: TWST] stock has seen the most recent analyst activity on November 04, 2025, when Stephens initiated its Overweight rating and assigned the stock a price target of $41. Previously, Wolfe Research started tracking the stock with Outperform rating on December 13, 2024, and set its price target to $60. On June 04, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $53 on the stock. Goldman upgraded its rating to a Buy and increased its price target to $45 on January 17, 2024. Berenberg initiated its recommendation with a Buy and recommended $27 as its price target on September 27, 2023. Scotiabank started tracking with a Sector Outperform rating for this stock on January 05, 2023, and assigned it a price target of $33. In a note dated January 03, 2023, Evercore ISI upgraded an Outperform rating on this stock and boosted its target price from $28 to $36.
Twist Bioscience Corp [TWST] stock has fluctuated between $23.30 and $55.33 over the past year. Currently, Wall Street analysts expect the stock to reach $40.67 within the next 12 months. Twist Bioscience Corp [NASDAQ: TWST] shares were valued at $40.22 at the most recent close of the market. An investor can expect a potential return of 1.12% based on the average TWST price forecast.
Analyzing the TWST fundamentals
Twist Bioscience Corp [NASDAQ:TWST] reported sales of 376.57M for the trailing twelve months, which represents a growth of 16.88%. Gross Profit Margin for this corporation currently stands at 0.51% with Operating Profit Margin at -0.36%, Pretax Profit Margin comes in at -0.2%, and Net Profit Margin reading is -0.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.17 and Total Capital is -0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Twist Bioscience Corp’s Current Ratio is 3.64. In addition, the Quick Ratio stands at 3.33 and the Cash Ratio stands at 2.0. Considering the valuation of this stock, the price to sales ratio is 6.54, the price to book ratio is 5.16.
Transactions by insiders
Recent insider trading involved Laponis Adam, Chief Financial Officer, that happened on Jan 09 ’26 when 2738.0 shares were sold. Officer, Finn Patrick John completed a deal on Jan 13 ’26 to buy 23279.0 shares. Meanwhile, Officer Laponis Adam bought 3000.0 shares on Jan 13 ’26.
